Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
Briacell Therapeutics Corp (BCTX) is a clinical-stage biotechnology company pioneering novel immunotherapies for cancer treatment. This page serves as the definitive source for verified news and official updates regarding the company’s research initiatives, clinical trial progress, and strategic developments.
Investors and industry professionals will find timely updates on key programs including the Bria-IMT Phase 3 trial for metastatic breast cancer and the Bria-OTS platform’s expansion into additional oncology applications. The resource consolidates press releases, regulatory filings, and partnership announcements to provide comprehensive tracking of the company’s progress in immuno-oncology.
Content highlights include clinical trial milestones, peer-reviewed research publications, manufacturing updates, and executive commentary. All materials are sourced directly from company disclosures to ensure accuracy and compliance with financial reporting standards.
Bookmark this page for streamlined access to Briacell’s latest developments in targeted cell-based immunotherapies. Check regularly for updates on pivotal studies and emerging data from their innovative cancer treatment platforms.
BriaCell Therapeutics, a clinical-stage biotech firm, has closed a $5.0 million registered direct offering with institutional and existing investors, including a director. The offering involves the sale of 2,402,935 common shares and warrants, with each unit priced at $2.00 to $2.215. The proceeds will fund working capital, R&D, a Phase 3 breast cancer study, and legal costs. A.G.P./Alliance Global Partners acted as the sole placement agent. The offering has been conducted under an existing shelf registration statement filed with the SEC.
BriaCell Therapeutics announced a $5.0 million registered direct offering, involving the sale of 2,402,935 common shares or pre-funded warrants and warrants to institutional investors and a director. The shares are priced at $2.00 each for institutional investors and $2.215 for the director, with warrants exercisable at $2.11 within six months and expiring in five years. The proceeds will support working capital, R&D, including a Phase 3 study in advanced breast cancer, and potential share repurchases. The offering closes around May 17, 2024, subject to customary conditions.
FAQ
What is the current stock price of Briacell Therapeutics (BCTX)?
What is the market cap of Briacell Therapeutics (BCTX)?
